Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05587712 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
A Phase 2 study of Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 20
- Study locations
NCT05587712 is a Phase 2 study of Pulmonary Arterial Hypertension that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 42 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT05587712, a Phase 2 study of Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to \<18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.
Conditions Studied
Interventions
- DRUG Sotatercept
Study Locations (20)
California
- The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606) - Los Angeles
- Stanford University School of Medicine ( Site 1603) - Palo Alto
- UCSF Benioff Children's Hospital San Francisco ( Site 1611) - San Francisco
Valle del Cauca Department
- Fundación Valle del Lili ( Site 0200) - Cali
- Clínica Imbanaco S.A.S ( Site 0203) - Cali
Colorado
- Children's Hospital Colorado ( Site 1609) - Aurora
District of Columbia
- Children's National Medical Center ( Site 1600) - Washington D.C.
Ohio
- Cincinnati Children's Hospital Medical Center ( Site 1602) - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia (CHOP) ( Site 1608) - Philadelphia
Tennessee
- Monroe Carell Jr. Children's Hospital ( Site 1601) - Nashville
Washington
- Seattle Children's Hospital ( Site 1605) - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-01-19 |
| Est. Completion | 2028-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05587712
The ClinicalTrials.gov registry entry for NCT05587712 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (91% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Sotatercept is the first listed.
NCT05587712 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Valle del Cauca Department, Colorado.
Frequently Asked Questions
What is clinical trial NCT05587712 about?
NCT05587712 is a clinical study titled "Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)". The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to \<18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.
What is the current status of trial NCT05587712?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2023-01-19. Estimated completion is 2028-09-21.
What conditions does trial NCT05587712 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT05587712?
The interventions under investigation include: Sotatercept (DRUG).
Who is sponsoring clinical trial NCT05587712?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05587712 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
Repurposing Valsartan May Protect Against Pulmonary Hypertension
RECRUITING · Phase 2
-
Spironolactone for Pulmonary Arterial Hypertension
RECRUITING · Phase 2
-
129 Xenon Imaging in Patients Treated With Sotatercept
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.